This trial will test the safety of a drug not approved for alcoholic liver disease in up to 24 patients. The goal is to also establish if the drug is effective in treating the disease by measuring biomarkers for liver inflammation and fibrosis.
1 Primary · 0 Secondary · Reporting Duration: 48 Weeks
24 Total Participants · 3 Treatment Groups
Primary Treatment: Guselkumab 100mg · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: